Pancreatic cancer poses biomedical challenges so complex that even advancements that represent modest improvements for patients are considered crucial in research. This is the case with the new drugs that target the oncogene KRAS, currently being trialled for this and other types of cancer: they are opening cracks in a decade-long impassable wall. Cracks that … Continue reading New drug in trial for the main oncogene in pancreatic cancer: one small step for patients, one giant leap for research